

<b>DATE</b>	25 June 2026
<b>SUBJECT</b>	Strategic AI collaboration to map CB-24 sensitivity and resistance across 831 oncology cell lines, informing IND, Orphan Drug Designation and Phase II strategy.
<b>CONTACT</b>	Media enquiries as listed below.

## Celtic Biotech Announces AI Collaboration with Meta-Flux to Advance First-in-Class Cancer Candidate CB-24

*Meta-Flux’s AI platform will analyse Celtic Biotech’s lead candidate CB-24 across 831 oncology cell lines to prioritise targets, sharpen patient stratification and inform the company’s regulatory strategy.*

Celtic Biotech Ltd, Pharma Industry Biotech Company of the Year 2025, is pleased to announce its recently inked collaboration with Meta-Flux, an award-winning AI platform for de-risking drug development pipelines.

Meta-Flux, an Irish computational-biology company and recent winners of the prestigious MassBio Startup 2026, will apply its AI platform and harmonised multi-omics reference data to develop insights into sensitivity and resistance patterns across 831 oncology cell lines, made available by the Broad Institute, Cambridge, MA, and treated with Celtic Biotech’s lead candidate CB-24. With a remarkable 63% of lung, 61% of Breast and 43% of Pancreatic cancer cell lines indicating various levels of sensitivity in initial analysis, Meta-Flux’s platform resolves signals that conventional multivariate methods struggle to uncover. Meta-Flux’s platform will generate prioritised candidates (genes, proteins and pathways) with predictive-accuracy metrics. Delivering high-fidelity analyses harnessing AI predictions built with 20 billion harmonised multi-omics and clinical data points, Meta-Flux will help inform Celtic’s IND applications, Orphan Drug Designation filings and Phase II patient-stratification strategy.

*“We’re delighted to be working with Celtic Biotech. We expect this collaboration to reinforce the science on both sides, and by pointing to disease candidates and patient populations most likely to benefit from CB-24, we expect it to significantly speed its clinical development.”*

**LEE SHERLOCK** · CEO & CO-FOUNDER, META-FLUX

*“The discovery side of AI in drug development is accelerating. More targets are coming through pipelines than ever before. But more targets don’t mean better targets. The bottleneck has shifted from finding candidates to triaging and validating them. CB-24 is a very exciting prospect in this regard.”*

**BRENDAN MARTIN** · CTO, META-FLUX

*“This collaboration, co-funded by the European Innovation Council Access+ programme, has the potential to cut years off our clinical development programme, boost our IP portfolio and help us develop lifechanging treatments for patients facing very grim prognoses, having failed all conventional treatments.”*

**PAUL REID** · CEO & CO-FOUNDER, CELTIC BIOTECH

*“We have every confidence that Meta-Flux is the right team, in the right place at the right time to help us bring CB-24, our first in class game-changing clinical asset, into the cancer therapeutic field.”*

**JOHN REID** · COO & CO-FOUNDER, CELTIC BIOTECH

# # #

### About Celtic Biotech

Celtic Biotech is an Irish oncology company harnessing specialised peptides purified from snake-venom neurotoxins to create safer, more selective treatments for solid-tumour cancers and the severe pain that often accompanies them. Its lead therapeutic, CB-24 (crotoxin), is a first-in-class dual function agent that targets multiple nicotinic acetylcholine receptors subtypes, targets that are over-expressed on malignant cells, then releases its PLA2 subunit to rupture the tumour membrane and trigger programmed cell death. Its specificity contributes to sparing healthy tissue. CB-24 is being advanced for some of the deadliest solid cancers, including non-small-cell lung, breast, pancreatic, prostate, ovarian and cervical tumours, with the goal of improving survival and quality-of-life at a cost that patients and health systems can bear.

### About Meta-Flux

Meta-Flux is harnessing AI predictions built with 20 billion harmonised multi-omics and clinical data points to build high-fidelity, holistic disease maps: layered atlases that chart pathology tissue by tissue and cell by cell. The Meta-Flux approach leverages network modelling to trace how genes, proteins and metabolic circuits converge to drive disease trajectories and drug response. This approach can enable actionable targets, flag safety liabilities early, and reveal repurposing or alternative-indication opportunities across oncology and CNS.

Media Contacts:

John Reid, COO  
[info@celticbiotech.com](mailto:info@celticbiotech.com)  
[www.celticbiotech.com](http://www.celticbiotech.com)

Brendan Martin, CTO  
[hello@meta-flux.com](mailto:hello@meta-flux.com)  
[www.meta-flux.com](http://www.meta-flux.com)

European  
 Innovation  
 Council

